Background
==========

Tuberculosis (TB) remains one of the most important infectious diseases worldwide. According to estimates of the World Health Organization (WHO), 3 hundred million people were infected by *Mycobacterium tuberculosis* and 30 million people died of TB from 2001 to 2010 \[[@B1],[@B2]\]. In Taiwan, the incidence of TB remains high (58 per 100,000 population in 2009) \[[@B3]\]. To prevent further transmissions, early diagnosis and timely treatment are the most important strategies \[[@B4],[@B5]\].

Patients infected with *M. tuberculosis* will develop latent TB infection (LTBI), a major source of active TB \[[@B6]\]. Previous studies show that about 10% of LTBI patients will develop the active disease and this risk is even higher in immuno-compromised hosts \[[@B7],[@B8]\]. Nowadays, LTBI is detected by tuberculin skin test and by interferon-gamma release assay (IGRA), which measures T-cell response against tuberculous bacilli-specific antigen \[[@B9]-[@B11]\]. In particular, IGRA is reportedly more accurate in diagnosing LTBI and as an indicator of progression to active TB \[[@B12]\]. However, factors predicting the development of active TB from LTBI remain ineffective. Active TB is still identified mainly by traditional chest imaging and mycobacteriologic study.

In the pathogenesis of TB, macrophages are the first-line of defense as the TB bacilli enter the airways \[[@B13]\]. Phagocytosis of the bacilli is then performed by phagocytic antigen-presenting cells in the lungs. However, *M. tuberculosis* has several mechanisms for persisting in human tissues \[[@B14]-[@B16]\]. For instance, necrosis of *M. tuberculosis*-infected macrophages as the dominant form of cell death instead of apoptosis \[[@B15],[@B17]\] prevents the removal of intracellular bacilli and the more efficient induction of inflammation \[[@B18]\].

Apoptosis-associated markers, including Decoy receptor-3 (DcR-3), lipoxin, and prostaglandin E2 (PGE2) have rarely been investigated for discriminating active TB from LTBI in clinical practice. Among them, DcR3 is a receptor of the tumor necrosis factor (TNF) receptor super-family, existing as a soluble receptor for Fas ligand, a well-known marker in the extrinsic pathway of apoptosis, and is considered an immuno-modulator \[[@B19]\]. The latter two lipid markers antagonize macrophage apoptosis in an animal model when infected with *M. tuberculosis*\[[@B17],[@B20]\]. Thus, this prospective study enrolled active TB cases and IGRA-positive and IGRA-negative family contacts and compared serum apoptosis-associated markers to identify potentially discriminative diagnostic and prognostic factors.

Methods
=======

Enrolment of patients and contacts
----------------------------------

This prospective study was conducted in a tertiary-care referral center in northern Taiwan and its branch, a local teaching hospital in southern Taiwan. The Research Ethics Committee of National Taiwan University Hospital approved the study (No. 9561707008). From January 2009 to June 2011, adult patients (age \>20 years) with culture- or histology-confirmed active TB were prospectively identified \[[@B5]\]. After providing informed consent, they received peripheral blood sampling before (TB at diagnosis) and one month after anti-TB treatment (TB under treatment) for measurement of serum biomarker levels.

Family contacts with known results of an interferon-gamma release assay (IGRA)-T-SPOT*.TB* (Oxford Immunotech Ltd, Oxford, UK) were also enrolled. Family contacts with negative T-SPOT.*TB* were considered the non-infection group whereas family contacts with positive T-SPOT.*TB* were considered the LTBI group. The contacts received chest radiography and mycobacteriologic study (acid-fast smear and mycobacterial culture) from 3 sputum samples to exclude the possibility of active TB \[[@B5],[@B21]\].

Patients and contacts with human immunodeficiency virus infection and those with bleeding tendency were excluded. Contacts with symptoms compatible with acute infection were also excluded.

Measurements of biomarkers
--------------------------

Assays for apoptosis-associated markers, including lipid markers (lipoxin and prostaglandin E \[PGE\]-2) and decoy receptor (DcR)-3, cytokines (interleukin \[IL\]-6, IL-10, tumor necrosis factor \[TNF\]-alpha, and interferon \[IFN\]-gamma), chemokines (monocyte chemotactic protein \[MCP\]-1, macrophage inflammatory protein \[MIP\]-1alpha, and MIP-1beta) were performed using serum samples in one batch. All samples were performed in a random order by a technician blinded to the clinical diagnosis. The Bioplex Multiplex Suspension Array System (Bio-Rad *Laboratories Taiwan Ltd.*) \[[@B22]\] was used for all chemokines and cytokines, while the ELISA method was used for lipoxin (Biosource, California, US), PGE2, and DcR3 (R&D Systems Europe, Abingdon, UK).

The lower limits of detection for IL-6, IL-10, IFN-gamma, TNF-alpha, MCP-1, MIP-1alpha, MIP-1beta, DcR3, lipoxin and PGE2 were 1.23, 1.81, 1.8, 4.72, 1.61, 1.4, 1.4, 93.7, 780, and 7.8 pg/ml, respectively. If serum levels of a sample were below the detection range, it was noted as half of the lower limit, i.e. 0.615, 0.905, 0.9, 2.36, 0.805, 0.7, 0.7, 46.85, 390, and 3.9 pg/ml, respectively.

Data collection
---------------

Clinical data, including age, sex, underlying co-morbidities, history of pulmonary TB, laboratory data, and results of acid-fast smear, mycobacterial culture, and drug susceptibility test, as well as anti-TB treatment course and outcomes were all recorded in a standardized case report form. Chest imaging was reviewed and noted as in a previous study \[[@B23]\]. The TB patients were followed-up for at least six months after anti-TB treatment or until death or loss to follow-up.

Statistical analysis
--------------------

Serum levels of biomarkers among TB patients and family contacts were compared. Inter-group differences were analyzed by independent sample *t* test or one-way analysis of variance (ANOVA) for numerical variables, and by *chi*-square test for categorical variables. Multivariate logistic regression analysis was used to identify factors associated with TB among TB patients and family contacts with LTBI. For TB patients, survival curves were generated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards regression analysis was used to identify factors associated with six-month survival.

In the stepwise variable selection procedure, all potential predictors were included. A two-sided *p*\<0.05 was considered significant. The discriminative power of each biomarker for 1) active TB from LTBI and 2) mortality from survival in TB patients was analyzed using the receiver operating characteristic (ROC) curve and area under the curve (AUC). The optimal cut-off value, defined as the one with the least (1 - sensitivity)^2^ + (1 - specificity)^2^, was used to calculate sensitivity and specificity \[[@B24]\]. All analyses were performed using the SPSS (Version 13.0, Chicago, IL).

Results
=======

During the study period, 100 TB patients (TB at diagnosis group), 92 IGRA-negative (non-infection group), and 91 IGRA-positive (LTBI group) family contacts were enrolled. The TB patients were significantly older, with male predominance, and had higher proportion of prior TB history and underlying co-morbidity compared to the family contacts (Table [1](#T1){ref-type="table"}). Among the 100 TB patients, 55 received follow-up blood sampling one month after anti-TB treatment (TB under treatment group).

###### 

Clinical characteristics of patients with tuberculosis (TB) and family contacts by responses to interferon-gamma release assay

                      **IGRA-negative contacts n=92**   **IGRA-positive contacts n=91**   **TB patients n=100**   ***p*value**
  ------------------- --------------------------------- --------------------------------- ----------------------- --------------
  Age (years)         44.6 \[16.9\]                     51.3 \[15.6\]                     70.3 \[16.2\]           \<0.001
  Male sex            32 (35%)                          33 (36%)                          62 (62%)                \<0.001
  History of TB       0                                 0                                 10 (10%)                \<0.001
  Co-morbidity        3 (3%)                            7 (8%)                            39 (39%)                \<0.001
  Diabetes mellitus   2 (2%)                            5 (6%)                            30 (30%)                \<0.001
  Malignancy          1 (1%)                            3 (3%)                            15 (15%)                \<0.001
  Liver cirrhosis     0                                 0                                 2 (2%)                  0.158

Data are no. (%) or mean \[standard deviation\].

Between the non-infection and LTBI groups, there was no significant difference in serum levels of biomarkers except for MCP-1 (27.86 vs. 18.30 pg/ml, *p*=0.039). Between the LTBI and TB at diagnosis groups, IL-6 (2.7 vs. 64 pg/ml, *p*=0.018), MCP-1 (18.30 vs. 34.05, *p*=0.043), DcR3 (0.64 vs. 3.97 ng/ml, *p*\<0.001), and PGE2 (0.31 vs. 3.04, *p*=0.001) were significantly higher in the latter, whereas lipoxin (3.391 vs. 1.73, *p*=0.008) was significantly higher in the former. All cytokines, DcR3, lipoxin, and PGE2 levels were not significantly different between TB patients with malignancy and those without. Serum levels of these markers were also not significantly different between the TB at diagnosis and TB under treatment groups (see online Additional file [1](#S1){ref-type="supplementary-material"}).

Among the four groups (i.e., non-infection group, LTBI group, TB at diagnosis group, and TB under treatment group), inflammatory cytokines, including IL-6, TNF-alpha, and IFN-gamma decreased from the non-infection group to the LTBI group, and then increased in the TB patients (Figure [1](#F1){ref-type="fig"}A). In contrast, IL-10 showed a continuous decreasing trend (statistically not significant). Regarding chemokines, the trend of MCP-1 was comparable to those of inflammatory cytokines but the trends of MIP-1alpha and MIP-1beta increased gradually from the non-infection group to the LTBI group to the TB group (Figure [1](#F1){ref-type="fig"}B). As for apoptosis-associated markers, the trends of DcR3 and PGE2 were similar to those of inflammatory cytokines but lipoxin had an opposite trend (Figure [1](#F1){ref-type="fig"}C).

![**Histogram shows serum levels of (A) cytokines, (B) chemokines, and (C) apoptosis-associated markers among family contacts and patient with tuberculosis.**Dx, diagnosis; Tx, treatment; \**p*\<0.050; \*\**p*\<0.010; \*\*\**p*\<0.001.](1471-2334-13-45-1){#F1}

Multivariate logistic regression analysis for the LTBI and TB at diagnosis groups revealed that age and serum DcR3, PGE2, and lipoxin levels were independently associated with active TB (Table [2](#T2){ref-type="table"}). The results were similar in the sub-population analysis focusing on subjects without malignancy (*p*=0.007, *p*\<0.001, *p*=0.004, *p*=0.017, respectively). The AUC under the ROC curves of age, DcR3, PGE2, and lipoxin was 0.819, 0.932, 0.859, and 0.743, respectively (Figure [2](#F2){ref-type="fig"}). The optimal cut-off values were 67 years old (sensitivity 71%; specificity 87%), 1.14 ng/ml (sensitivity 87%; specificity 87%), 0.35 ng/ml (sensitivity 81%; specificity 79%), and 1.82 ng/ml (sensitivity 65%; specificity 82%), respectively. A combination of three biomarkers was used to predict the probability of active TB disease (Table [3](#T3){ref-type="table"}) and the presence of any two provided a sensitivity of 99% and specificity of 72%.

###### 

Factors significantly associated with tuberculosis (TB) in multivariate logistic regression analysis among contacts with latent TB infection and TB patients

  **Characteristics**              ***p*value**   **OR (95% C.I.)**
  -------------------------------- -------------- ---------------------
  Age, per 1 year increment        0.003          1.07 (1.02-1.11)
  DcR 3, per 1 ng/mL increment     \<0.001        11.91 (4.03-35.17)
  Lipoxin, per 1 ng/mL increment   \<0.001        0.39 (0.23-0.66)
  PGE2, per 1 ng/mL increment      \<0.001        21.71 (4.66-101.28)

Abbreviations: TB, tuberculosis; DcR 3, decoy receptor 3; PGE2, prostaglandin E2.

![Receiver operating characteristic curves of factors independently associated with tuberculosis among interferon-gamma release assay (IGRA)-positive contacts and patients with tuberculosis.](1471-2334-13-45-2){#F2}

###### 

Predicting the presence of tuberculosis (TB) by biomarkers

  **Conditions**   **No. of matched subjects**   **TB patients**   **Sensitivity**   **Specificity**   **Positive predictive value**   **Negative predictive value**
  ---------------- ----------------------------- ----------------- ----------------- ----------------- ------------------------------- -------------------------------
  All              59                            51                51%               92%               86%                             65%
  Any two          127                           99                99%               72%               78%                             99%
  Anyone           140                           99                99%               59%               71%                             98%

The three clinical factors included were Decoy receptor 3 (DcR3) \>1.14 ng/mL, prostaglandin E2 (PGE2) \>0.35 ng/mL, and lipoxin \<1.82 ng /mL.

Among the 100 TB patients, 21 (21%) died (of any cause) during the study. Comparing the clinical characteristics, survivors were younger and less likely to have underlying co-morbidity. Non-survivors had higher serum MCP-1 (*p*=0.012) and DcR3 (*p*=0.078) levels (Table [4](#T4){ref-type="table"}).

###### 

Clinical characteristics, laboratory results, radiologic findings and disease extent among patients with tuberculosis (TB)

                         **Survivors n=79**   **Non-survivors n=21**   ***p*value**
  ---------------------- -------------------- ------------------------ --------------
  Age (years)            68.2 \[16.9\]        78.3 \[9.6\]             0.010
  Male sex               48 (61%)             14 (67%)                 0.620
  History of TB          6 (8%)               4 (19%)                  0.120
  Co-morbidity           27 (34%)             12 (57%)                 0.055
  Diabetes mellitus      24 (30%)             6 (29%)                  0.872
  Malignancy             6 (8%)               9 (43%)                  \<0.001
  Liver cirrhosis        0                    2 (10%)                  0.006
  Diagnosis evidence                                                   0.051
  Culture positive       79 (100%)            20 (95%)                  
  Pathology positive     0                    1 (5%)                    
  Mtb resistance                                                        
  INH resistance         8 (10%)              0                        0.128
  RIF resistance         0                    1 (5%)                   0.051
  Sputum AFS-positive    52 (66%)             11 (52%)                 0.257
  Radiographic pattern                                                  
  Upper lung lesion      53 (67%)             13 (62%)                 0.656
  Cavitation             11 (14%)             1 (5%)                   0.251
  Disease extent                                                       0.653
  Pulmonary              64 (81%)             18 (86%)                  
  Extra-pulmonary only   3 (4%)               0                         
  Mixed                  12 (15%)             3 (14%)                   
  Blood tests                                                           
  Leukocyte, (/μL)       9609 \[4880\]        10297 \[4207\]           0.542
  Interleukin-6          54.9 \[257.3\]       98.2 \[196.6\]           0.408
  Interleukin-10         5.6 \[23.1\]         4.7 \[12.2\]             0.814
  Interferon-gamma       66.3 \[472.7\]       15.4 \[38.9\]            0.347
  TNF-alpha              50.8 \[375.5\]       32.7 \[123.7\]           0.720
  MCP-1                  25.0 \[50.1\]        68.2 \[116.1\]           0.012
  MIP-1alpha             6.1 \[29.8\]         1.8 \[2.6\]              0.210
  MIP-1beta              245.4 \[1274.7\]     193.3 \[366.2\]          0.752
  Decoy receptor 3       3.6 \[3.8\]          5.3 \[3.7\]              0.078
  Lipoxin                1.7 \[1.5\]          1.7 \[1.2\]              0.939
  Prostaglandin E2       2.9 \[8.1\]          3.4 \[7.0\]              0.793

Data are no. (%) or mean \[standard deviation\].

Abbreviations: MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; TNF, tumor necrosis factor.

Using the optimal cut-off values determined by ROC curve analysis, the Kaplan-Meier survival curves of TB patients according to serum MCP-1 (\>28.72 *vs*. ≤28.72 pg/ml) and DcR3 (\>2.67 *vs*. ≤2.67 ng/ml) levels were plotted (Figure [3](#F3){ref-type="fig"}). The *p* values compared by log-rank test were 0.002 and 0.004, respectively. Multivariate Cox regression analysis revealed that age, co-morbidity, and serum MCP-1 and DcR3 levels were independent factors predicting six-month survival (Table [5](#T5){ref-type="table"}).

![Survival curves plotted using the Kaplan-Meier method for patients with tuberculosis and different serum levels of (A) MCP-1 and (B) DcR3.](1471-2334-13-45-3){#F3}

###### 

Factors independently associated with worse six-month survival in patients with tuberculosis, by Cox proportional hazards regression analysis

  **Characteristics**            ***p*value**   **HR (95% C.I.)**
  ------------------------------ -------------- ----------------------
  Age, per 1 year increment      0.008          1.072 (1.018-1.129)
  Co-morbidity                   0.007          3.856 (1.450-10.256)
  DcR 3, per 1 ng/mL increment   0.046          1.089 (1.001-1.183)
  MCP, per 1 pg/mL increment     \<0.001        1.008 (1.004-1.013)
  PGE2, per 1 ng/mL increment    0.063          1.059 (0.997-1.125)

Abbreviations: DcR 3, Decoy receptor 3; MCP, monocyte chemotactic protein; PGE2, Prostaglandin E2.

Discussion
==========

Using four groups (i.e., non-infection group, LTBI group, TB at diagnosis group, and TB under treatment group) of data that represent the different stages in the development of active TB disease, the present study reveals that apoptosis-associated biomarkers change significantly. Levels of DcR3 and PGE2 are elevated but lipoxin is decreased when patients have active TB compared to latent infection. Combinations of the three biomarkers and age may be useful and promising tools in clinical practice to predict the development of active TB among family contacts with LTBI. As for TB patients, age and underlying co-morbidity, and serum DcR3 and MCP-1 levels at the time of diagnosis are significantly associated with six-month survival.

During latent infection, *M. tuberculosis* has several mechanisms to protect itself from human immunity \[[@B14]-[@B16]\]. One is the suppression of apoptosis of infected macrophages because this will result in the removal of intracellular bacilli and induction of inflammation \[[@B18],[@B25]\]. *M. tuberculosis* also promotes its replication by inhibiting the apoptosis of infected macrophages \[[@B18]\]. Macrophage death toward necrosis instead of apoptosis is therefore a considerably advantageous evasion mechanism of *M. tuberculosis*\[[@B26]\].

Later, there are overwhelming systemic inflammatory responses when active disease develops. Thus, levels of inflammatory cytokines decrease when subjects progress from non-infection status to latent infection, and peak in the active TB disease status. Although DcR3 and PGE2 levels have a similar trend, DcR3 may be a downstream (passive) responder to inflammation-related apoptosis and enhance the signal pathway. PGE2 plays a relatively active role in the upstream of apoptosis \[[@B19],[@B27],[@B28]\]. In addition, the trend of lipoxin shows its function of antagonizing PGE2 in apoptosis control.

After *M. tuberculosis* infection, macrophages are activated locally and chemokines increase, leading to a gradual increase in serum MIP level from non-infection and LTBI to active TB. However, MCP-1 recruits monocytes and T lymphocytes later during the granulomatous response \[[@B29]\] and may not significantly increase during LTBI. This explains the similar trend of change as inflammatory cytokines.

Apoptosis-associated biomarkers, rather than inflammatory cytokines, are independent factors in predicting active TB. They are of practical importance yet remain largely unexplored. This is probably because inflammatory cytokines may be influenced by multiple factors during inflammation, whereas apoptosis-associated biomarkers are much simpler in their pathways and have less influence. Although apoptosis-associated markers may be confounded by underlying co-morbidity, the association between these markers and active TB is probably independent of underlying co-morbidity, based on the results of the current analyses.

Among the apoptosis-associated biomarkers, DcR3 seems to be the most associated with immune cells \[[@B19],[@B28],[@B30]\]. It has the potential to discriminate between latent and active TB using the ROC curve analysis. From a public health consideration, a test with high sensitivity for predicting the development of active TB from LTBI is most useful in preventing delayed TB diagnosis and further transmission. If 99% of active TB cases can be identified by DcR3 \>1.14 ng/ml plus PGE2 \>0.35 ng/ml, these will be useful as screening criteria.

The six-month survival of TB patients may be confounded by numerous factors and is difficult to predict simply based on characteristics at diagnosis. Many influential factors may be missed in the analysis. Nonetheless, the results imply that baseline health conditions and extent of immune response to TB have prognostic importance. DcR3 has been reported as an immuno-modulator that skews immune response into type II macrophages but also induces dendritic cell apoptosis \[[@B28],[@B30]\]. Hence, it may be a promising indicator of overwhelming inflammatory response for destruction during active TB. As a potent recruiting signal for monocytes and T cells \[[@B31]\], higher serum MCP-1 level may imply more severe granulomatous inflammation \[[@B29]\]. This is the first time that MCP-1 level in TB patients is demonstrated as a promising tool for outcome prediction.

This study has some limitations. First, inter-group comparison is performed in different individuals and may be biased by individual variations. Disease processes other than TB, like cancer, may influence serum levels of biomarkers. Second, biomarker responses after *in vitro* stimulation are not assayed. Thus, it cannot be simply concluded that the measured levels of biomarkers in study subjects are solely due to immune response against *M. tuberculosis*. Third, the study was conducted in a tertiary referral center and a regional teaching hospital. The high prevalence of underlying co-morbidities in TB patients may change the serum levels of biomarkers and lead to a relatively high mortality rate. This limits the external generalization of the study results. Furthermore, due to the small number of follow-up samples, firm conclusions cannot be made for the biomarker levels after treatment.

Conclusion
==========

In conclusion, apoptosis-associated markers significantly correlate with the status of *M. tuberculosis* infection. High DcR3 level, high PGE2 level, and low lipoxin level may be highly sensitive criteria for identifying active TB cases among contacts with LTBI. Prognosis is poorer in TB patients with older age, underlying co-morbidity, and high serum DcR3 and MCP-1 levels.
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